ERYTECH Announces the Availability of the Documents for its Annual General Meeting to be held on June 24, 2022
24 Mayo 2022 - 3:05PM
ERYTECH Announces the Availability of the Documents for its Annual
General Meeting to be held on June 24, 2022
ERYTECH Announces the
Availability of the Documents for its Annual General Meeting to be
held on June 24,
2022
Cambridge, MA (U.S.) and Lyon
(France), May
24, 2022 –
ERYTECH Pharma
(Nasdaq &
Euronext: ERYP), a
clinical-stage biopharmaceutical company
developing innovative therapies by encapsulating
therapeutic drug substances inside red blood
cells, today
announced the availability of the
documents for its Annual General Meeting to be held on
Friday, June 24,
2022.
ERYTECH’s shareholders are hereby informed of
the Annual General Meeting which will be held on June 24, 2022 at
09:00am CEST at the Hôtel Intercontinental Paris – Le Grand, 2 rue
Scribe, 75009 Paris (FRANCE).
Shareholders may participate in the General
Meeting as follows:
- Attend in person;
- Voting by mail or by internet on
the secure voting platform Votaccess; or
- Give a proxy to any individual or
legal entity of their choice, under the applicable legal and
regulatory conditions, or give a proxy to the Chairman of the
Shareholders' Meeting. The Chairman will then vote on their behalf
in favor of the adoption of the draft resolutions presented or
approved by the Board of Directors and against the adoption of all
other draft resolutions.
Availability of the documents for the
Shareholders’ Meeting
The notice of meeting including the agenda and
the draft resolutions, together with the principal details for
attending and voting at the Combined Shareholders’ Meeting was
published in the French Bulletin of Legal Announcements no. 59 on
May 18, 2022.
Shareholders have access to the preparatory and
information documents for the Shareholders’ Meeting as provided for
by law and the regulations. They may also be viewed on the
Company’s website at:
https://investors.erytech.com/general-meeting.
Shareholders are kindly advised to consult this
section on a regular basis, as it may be updated to specify the
final terms and conditions of participation in this Shareholders'
Meeting, in accordance with sanitary and/or legal and regulatory
requirements.
About ERYTECH and eryaspase
(GRASPA®) www.erytech.com
ERYTECH is a clinical-stage biopharmaceutical
company developing innovative red blood cell-based therapeutics for
severe forms of cancer and orphan diseases. Leveraging its
proprietary ERYCAPS® platform, which uses a novel technology to
encapsulate drug substances inside red blood cells, ERYTECH is
developing a pipeline of product candidates for patients with high
unmet medical needs. ERYTECH’s primary focus is on the development
of product candidates that target the altered metabolism of cancer
cells by depriving them of amino acids necessary for their growth
and survival.
The Company’s lead product candidate, eryaspase,
which consists of L-asparaginase encapsulated inside donor-derived
red blood cells, targets the cancer cells’ altered asparagine and
glutamine metabolism. The proof of concept of eryaspase as a cancer
metabolism agent was established in different trials in acute
lymphoblastic leukemia (ALL) and pancreatic cancer. An investigator
sponsored Phase 2 trial (IST) evaluating the use of eryaspase in
ALL patients who developed hypersensitivity reactions to pegylated
asparaginase recently reported positive results, based on which the
Company intends to request approval in the United States and
potentially other territories. The Company is also pursuing a Phase
1 investigator-sponsored clinical trial in first-line pancreatic
cancer.
Eryaspase received Fast Track designation from
the U.S. Food and Drug Administration (FDA) for the treatment of
advanced pancreatic cancer and treatment of acute lymphoblastic
leukemia (ALL) patients who have developed hypersensitivity
reactions to E. coli-derived pegylated asparaginase. The FDA and
the European Medicines Agency have granted eryaspase orphan drug
status for the treatment of pancreatic cancer and ALL. Eryaspase is
not an approved medicine.
ERYTECH produces its product candidates for
treatment of patients in Europe at its GMP-approved manufacturing
site in Lyon, France, and expects to be able to produce for
patients in the United States through an anticipated long-term
supply agreement with Catalent, operating from ERYTECH’s former GMP
facility in Princeton, New Jersey, USA.
ERYTECH is listed on the Nasdaq Global Select
Market in the United States (ticker: ERYP) and on the Euronext
regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP).
ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC
Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next
Biotech
indexes.
CONTACTS
ERYTECH
Eric SoyerCFO & COO |
NewCapMathilde Bohin / Louis-Victor
DelouvrierInvestor relationsNicolas
MerigeauMedia relations |
+33 4 78 74 44
38investors@erytech.com |
+33 1 44 71 94 94
erytech@newcap.eu |
- PR_ERYTECH_2022 General Meeting_vf
Phaxiam Therapeutics (LSE:0QSS)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Phaxiam Therapeutics (LSE:0QSS)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024